Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chukwuemeka V. Ikpeazu"'
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Abstract METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) are established oncogeni
Externí odkaz:
https://doaj.org/article/9861e56c012246ee8994001ee6e06106
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Abstract The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approaches. RET gene fusions are oncoge
Externí odkaz:
https://doaj.org/article/67f46a88af534e2eaafca57707e604e2
Autor:
Chukwuemeka V Ikpeazu
Publikováno v:
Head and Neck Cancer Research.
The survival rate at 3 years after potentially curative surgical or radiation treatment for locally advanced squamous cell carcinoma of head and neck (SCCHN) remains quite poor at 30 to 50%. Over 50% of these patients relapse locally or at distant si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5dd8564e7f6e32f311553a74dc2f965
https://doi.org/10.21767/2572-2107.100004
https://doi.org/10.21767/2572-2107.100004
Publikováno v:
Applied Biological Chemistry; 11/1/2024, Vol. 67 Issue 1, p1-9, 9p
Autor:
Drusbosky, Leylah M.1 (AUTHOR), Dawar, Richa2 (AUTHOR), Rodriguez, Estelamari2 (AUTHOR), Ikpeazu, Chukwuemeka V.2,3 (AUTHOR) cikpeazu@med.miami.edu
Publikováno v:
Journal of Hematology & Oncology. 8/23/2021, Vol. 14 Issue 1, p1-10. 10p.
Publikováno v:
Journal of Hematology & Oncology; 3/26/2021, Vol. 14 Issue 1, p1-8, 8p